Fluoxetine Hydrochloride side effects: what 126,801 FDA adverse event reports show
Drug class
Not stated in label
Who reports
126,801 reports · 72% serious · 12,911 with death outcome · 72% female
Used for
Fluoxetine capsules are indicated for the treatment of: • Acute and maintenance treatment of Major Depressive Disorder [ see Clinical Studies (14.1)]. • Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD) [ see Clinical Studies (14.2 )].
What it is
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine is an aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Boxed warning
SUICIDAL THOUGHTS AND BEHAVIORS • Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the r.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled — boxed warning The term (or its clinical synonym) appears in the FDA boxed warning: causality is regulator-recognised and considered serious.
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,144 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Antidepressant drug level increased | 91 | 56.5 44.5–71.8ROR 56.6 · calibrated p 8e-6 ✓ | 41.8 EB05 35.1 · IC025 +4.8 3/3 methods agree | Lab value / disease marker | serious n=91 · ♀ 0% (drug 72%) · 100% clinician | not reported in cached trials |
| Antipsychotic drug level below therapeutic | 172 | 54.3 45.7–64.5ROR 54.3 · calibrated p 9e-6 ✓ | 40.7 EB05 35.9 · IC025 +4.9 3/3 methods agree | Lab value / disease marker | serious n=169 · ♀ 0% (drug 72%) · 100% clinician | not reported in cached trials |
| Amaurosis fugax | 229 | 44.9 38.8–52.0ROR 45.0 · calibrated p 3e-5 ✓ | 35.3 EB05 31.6 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious n=229 · 100% clinician | not reported in cached trials |
| Persistent foetal circulation | 92 | 28.8 23.1–35.9ROR 28.8 · calibrated p 4e-4 ✓ | 24.5 EB05 20.6 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=92 · 100% clinician | not reported in cached trials |
| Disinhibition | 226 | 26.8 23.3–30.9ROR 26.9 · calibrated p 5e-4 ✓ | 23.1 EB05 20.7 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=223 · ♀ 0% (drug 72%) | not reported in cached trials |
| Serotonin syndrome | 2,364 | 23.2 22.2–24.2ROR 23.6 · calibrated p 9e-4 ✓ | 20.4 EB05 19.7 · IC025 +4.3 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 16.4 · serious PRR 16.5 | not reported in cached trials |
| Physical deconditioning | 292 | 21.7 19.2–24.5ROR 21.8 · calibrated p 0.001 ✓ | 19.3 EB05 17.5 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=292 | not reported in cached trials |
| Autism | 118 | 21.3 17.6–25.8ROR 21.3 · calibrated p 0.002 ✓ | 18.9 EB05 16.2 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=116 · 100% consumer | not reported in cached trials |
| Congenital cardiovascular anomaly | 97 | 21.2 17.2–26.2ROR 21.2 · calibrated p 0.002 ✓ | 18.8 EB05 15.9 · IC025 +3.8 3/3 methods agree | Labeled (related wording) related wording | serious n=97 · 100% consumer | not reported in cached trials |
| Craniosynostosis | 96 | 20.4 16.5–25.2ROR 20.4 · calibrated p 0.002 ✓ | 18.2 EB05 15.3 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=96 · 100% consumer | not reported in cached trials |
| Talipes | 265 | 15.3 13.5–17.4ROR 15.4 · calibrated p 0.006 ✓ | 14.1 EB05 12.7 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=265 · ♀ 100% (drug 72%) | not reported in cached trials |
| Bezoar | 115 | 15.0 12.4–18.1ROR 15.0 · calibrated p 0.008 ✓ | 13.7 EB05 11.7 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=115 · ♀ 100% (drug 72%) · 100% clinician | not reported in cached trials |
| Reversible cerebral vasoconstriction syndrome | 162 | 14.8 12.6–17.4ROR 14.8 · calibrated p 0.008 ✓ | 13.6 EB05 11.9 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=162 · ♀ 100% (drug 72%) · 100% clinician | not reported in cached trials |
| Binge eating | 87 | 14.5 11.6–18.1ROR 14.5 · calibrated p 0.009 ✓ | 13.3 EB05 11.1 · IC025 +3.3 3/3 methods agree | Likely indication confounding term in indications | serious n=78 · ♀ 100% (drug 72%) · 100% consumer | not reported in cached trials |
| Major depression | 584 | 14.2 13.1–15.5ROR 14.3 · calibrated p 0.009 ✓ | 13.2 EB05 12.3 · IC025 +3.6 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious PRR 10.7 | not reported in cached trials |
| Obsessive-compulsive disorder | 595 | 13.1 12.0–14.2ROR 13.1 · calibrated p 0.012 ✓ | 12.2 EB05 11.4 · IC025 +3.5 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=523 · ♀ 36% (drug 72%) | not reported in cached trials |
| Homicide | 126 | 12.3 10.3–14.8ROR 12.3 · calibrated p 0.016 ✓ | 11.4 EB05 9.8 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=125 · ♀ 0% (drug 72%) | not reported in cached trials |
| Anorgasmia | 178 | 11.5 9.9–13.4ROR 11.5 · calibrated p 0.020 ✓ | 10.7 EB05 9.4 · IC025 +3.1 3/3 methods agree | Labeled adverse reaction exact term | serious n=145 · 100% consumer | not reported in cached trials |
| Suicidal behaviour | 269 | 11.3 10.0–12.8ROR 11.3 · calibrated p 0.021 ✓ | 10.6 EB05 9.5 · IC025 +3.2 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=266 | not reported in cached trials |
| Depersonalisation/derealisation disorder | 99 | 10.8 8.8–13.2ROR 10.8 · calibrated p 0.026 ✓ | 10.0 EB05 8.4 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=93 · ♀ 0% (drug 72%) · 100% consumer | not reported in cached trials |
| Flat affect | 138 | 10.6 8.9–12.6ROR 10.6 · calibrated p 0.027 ✓ | 9.9 EB05 8.6 · IC025 +3.0 3/3 methods agree | Labeled (related wording) related wording | serious n=104 | not reported in cached trials |
| Hyperreflexia | 212 | 10.6 9.2–12.2ROR 10.6 · calibrated p 0.027 ✓ | 9.9 EB05 8.8 · IC025 +3.1 3/3 methods agree | Labeled adverse reaction exact term | serious n=208 · 100% clinician | not reported in cached trials |
| Cleft palate | 117 | 10.6 8.8–12.8ROR 10.6 · calibrated p 0.028 ✓ | 9.8 EB05 8.4 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=117 | not reported in cached trials |
| Antipsychotic drug level increased | 169 | 10.5 9.0–12.3ROR 10.5 · calibrated p 0.028 ✓ | 9.8 EB05 8.6 · IC025 +3.0 3/3 methods agree | Lab value / disease marker | serious n=166 · ♀ 45% (drug 72%) · 100% clinician | not reported in cached trials |
| Clonus | 163 | 10.4 8.9–12.2ROR 10.4 · calibrated p 0.029 ✓ | 9.7 EB05 8.5 · IC025 +3.0 3/3 methods agree | Labeled adverse reaction exact term | serious n=160 · 100% clinician | not reported in cached trials |
| Oculogyric crisis | 116 | 9.6 8.0–11.6ROR 9.6 · calibrated p 0.039 ✓ | 8.9 EB05 7.6 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=111 · 100% clinician | not reported in cached trials |
| Self-injurious ideation | 228 | 9.5 8.3–10.8ROR 9.5 · calibrated p 0.039 ✓ | 8.9 EB05 8.0 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=214 | not reported in cached trials |
| Intentional self-injury | 1,086 | 9.4 8.8–9.9ROR 9.4 · calibrated p 0.039 ✓ | 8.9 EB05 8.4 · IC025 +3.0 3/3 methods agree | Reporting / coding artifact | serious PRR 7.2 | not reported in cached trials |
| Tearfulness | 228 | 9.2 8.0–10.5ROR 9.2 · calibrated p 0.044 ✓ | 8.6 EB05 7.7 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=207 | not reported in cached trials |
| Urinary tract disorder | 233 | 9.0 7.9–10.2ROR 9.0 · calibrated p 0.047 ✓ | 8.5 EB05 7.6 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=230 · 100% clinician | not reported in cached trials |
| Ventricular septal defect | 295 | 8.9 7.9–10.0ROR 8.9 · calibrated p 0.048 ✓ | 8.4 EB05 7.6 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=295 | not reported in cached trials |
| Derealisation | 107 | 8.7 7.1–10.5ROR 8.7 · calibrated p 0.054 | 8.1 EB05 6.8 · IC025 +2.7 3/3 methods agree | Not in label — unassessed | serious n=98 · ♀ 0% (drug 72%) · 100% consumer | not reported in cached trials |
| Akathisia (inner restlessness) | 682 | 8.6 8.0–9.3ROR 8.7 · calibrated p 0.052 | 8.2 EB05 7.7 · IC025 +2.9 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 8.2 · ♀ 44% (drug 72%) | not reported in cached trials |
| Atrial septal defect | 412 | 8.5 7.7–9.4ROR 8.5 · calibrated p 0.056 | 8.1 EB05 7.4 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious PRR 6.5 | not reported in cached trials |
| Gambling disorder | 133 | 8.5 7.1–10.1ROR 8.5 · calibrated p 0.057 | 7.9 EB05 6.9 · IC025 +2.7 3/3 methods agree | Not in label — unassessed | serious n=118 · 100% consumer | not reported in cached trials |
| Intentional overdose | 3,059 | 8.3 8.0–8.6ROR 8.5 · calibrated p 0.056 | 7.9 EB05 7.7 · IC025 +2.9 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 5.7 · serious PRR 6.6 | not reported in cached trials |
| Physical assault | 100 | 8.3 6.8–10.1ROR 8.3 · calibrated p 0.063 | 7.7 EB05 6.5 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=94 · ♀ 0% (drug 72%) · 100% consumer | not reported in cached trials |
| Electrocardiogram qrs complex prolonged | 243 | 8.2 7.2–9.3ROR 8.2 · calibrated p 0.062 | 7.8 EB05 7.0 · IC025 +2.7 3/3 methods agree | Lab value / disease marker | serious n=242 · 100% clinician | not reported in cached trials |
| Hostility | 122 | 8.2 6.8–9.8ROR 8.2 · calibrated p 0.064 | 7.7 EB05 6.6 · IC025 +2.6 3/3 methods agree | Labeled adverse reaction exact term | serious n=104 | not reported in cached trials |
| Torsade de pointes | 372 | 8.2 7.4–9.1ROR 8.2 · calibrated p 0.063 | 7.8 EB05 7.1 · IC025 +2.8 3/3 methods agree | Labeled (related wording) related wording | serious PRR 6.3 | not reported in cached trials |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Suicidality | 10,514 | 7.37.2–7.5 | signal |
| Depression | 7,411 | 4.44.3–4.5 | signal |
| Extrapyramidal | 2,739 | 4.44.2–4.6 | signal |
| Hyponatraemia | 1,338 | 2.82.6–2.9 | signal |
| Seizure | 2,861 | 2.42.3–2.5 | signal |
| Arrhythmia / qt | 2,630 | 2.32.2–2.3 | signal |
| Rhabdomyolysis / myopathy | 991 | 2.01.9–2.2 | raised |
| Fall / fracture | 4,557 | 2.01.9–2.1 | raised |
| Pancreatitis | 828 | 1.71.6–1.8 | raised |
| Dependence / withdrawal | 2,717 | 1.51.5–1.6 | raised |
| Kidney injury | 4,118 | 1.51.5–1.5 | raised |
| Hyperglycaemia / diabetes | 2,924 | 1.41.4–1.5 | raised |
| Gi bleeding | 1,538 | 1.41.3–1.5 | raised |
| Venous thromboembolism | 1,752 | 1.31.3–1.4 | raised |
| Hypoglycaemia | 753 | 1.31.2–1.4 | raised |
| Serious infection | 5,776 | 1.21.2–1.3 | raised |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Fluoxetine as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (0 of 40 signal terms matched).
- NCT03466346 — SMART-DAPPER: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research (N=2162, NA; 57 AE terms posted; arms: Stage 1: Interpersonal Psychotherapy (IP; Stage 1: Fluoxetine; Stage 2: IPT After Fluoxetine; Stage 2: Fluoxetine After IPT)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug ineffective (drug did not work) | 8,157 | 1.0 1.0–1.0ROR 1.0 · calibrated p 0.323 | 1.0 EB05 1.0 · IC025 -0.0 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 1.0 · serious PRR 1.3 | not reported in cached trials |
| Nausea | 7,464 | 1.6 1.5–1.6ROR 1.6 · calibrated p 0.710 | 1.6 EB05 1.5 · IC025 +0.6 | Labeled adverse reaction exact term | age-adj. PRR 1.3 · serious PRR 1.6 | not reported in cached trials |
| Fatigue (tiredness) | 7,394 | 1.6 1.5–1.6ROR 1.6 · calibrated p 0.716 | 1.6 EB05 1.5 · IC025 +0.6 | Labeled (related wording) related wording | age-adj. PRR 1.4 · serious PRR 1.5 | NCT03466346: 1/1,082 (0.1%) on Fluoxetine (serious AE) |
| Headache | 6,379 | 1.7 1.7–1.7ROR 1.7 · calibrated p 0.786 | 1.7 EB05 1.6 · IC025 +0.7 | Labeled adverse reaction exact term | age-adj. PRR 1.4 · serious PRR 1.8 | NCT03466346: 1/160 (0.6%) on Fluoxetine |
| Depression | 5,893 | 4.4 4.2–4.5ROR 4.5 · calibrated p 0.294 | 4.3 EB05 4.2 · IC025 +2.0 3/3 methods agree | Labeled — boxed warning synonym match | age-adj. PRR 3.6 · serious PRR 3.7 | not reported in cached trials |
| Anxiety | 5,767 | 3.4 3.3–3.5ROR 3.5 · calibrated p 0.483 | 3.3 EB05 3.3 · IC025 +1.7 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 3.0 · serious PRR 3.1 | not reported in cached trials |
| Dizziness | 5,222 | 1.7 1.7–1.8ROR 1.8 · calibrated p 0.814 | 1.7 EB05 1.7 · IC025 +0.7 | Labeled adverse reaction exact term | age-adj. PRR 1.5 · serious PRR 1.8 | NCT03466346: 1/160 (0.6%) on Fluoxetine |
| Diarrhoea (diarrhea) | 5,144 | 1.3 1.3–1.4ROR 1.3 · calibrated p 0.534 | 1.3 EB05 1.3 · IC025 +0.4 | Labeled adverse reaction exact term | age-adj. PRR 1.2 · serious PRR 1.2 | not reported in cached trials |
| Off label use (used outside approved label) | 5,112 | 1.0 0.9–1.0ROR 1.0 · calibrated p 0.289 | 1.0 EB05 1.0 · IC025 -0.1 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 0.9 · serious PRR 1.0 | not reported in cached trials |
| Pain | 5,015 | 1.4 1.3–1.4ROR 1.4 · calibrated p 0.552 | 1.3 EB05 1.3 · IC025 +0.4 | Not in label — unassessed | age-adj. PRR 1.3 · serious PRR 1.3 | NCT03466346: 1/1,082 (0.1%) on Fluoxetine (serious AE) |
| Drug interaction | 4,947 | 5.3 5.1–5.4ROR 5.5 · calibrated p 0.190 | 5.2 EB05 5.0 · IC025 +2.3 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 4.7 · serious PRR 4.4 | not reported in cached trials |
| Vomiting | 4,785 | 1.7 1.6–1.7ROR 1.7 · calibrated p 0.783 | 1.7 EB05 1.6 · IC025 +0.7 | Likely indication confounding term in indications; also in warnings | age-adj. PRR 1.4 · serious PRR 1.6 | not reported in cached trials |
| Dyspnoea (shortness of breath) | 4,691 | 1.4 1.3–1.4ROR 1.4 · calibrated p 0.568 | 1.4 EB05 1.3 · IC025 +0.4 | Labeled adverse reaction exact term | age-adj. PRR 1.2 · serious PRR 1.2 | not reported in cached trials |
| Fall | 4,335 | 2.2 2.1–2.2ROR 2.2 · calibrated p 0.945 | 2.2 EB05 2.1 · IC025 +1.1 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.1 · serious PRR 1.8 | not reported in cached trials |
| Toxicity to various agents | 4,324 | 4.3 4.2–4.5ROR 4.5 · calibrated p 0.301 | 4.3 EB05 4.2 · IC025 +2.0 3/3 methods agree | Not in label — unassessed | age-adj. PRR 3.8 · serious PRR 3.5 · 90% clinician | not reported in cached trials |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Amaurosis fugax — n=229, PRR 44.9
- Persistent foetal circulation — n=92, PRR 28.8
- Disinhibition — n=226, PRR 26.8
- Physical deconditioning — n=292, PRR 21.7
- Autism — n=118, PRR 21.3
- Craniosynostosis — n=96, PRR 20.4
- Talipes — n=265, PRR 15.3
- Bezoar — n=115, PRR 15.0
- Reversible cerebral vasoconstriction syndrome — n=162, PRR 14.8
- Homicide — n=126, PRR 12.3
✓ A hand-written Bradford Hill causality assessment exists for this drug: Fluoxetine ↔ Serotonin syndrome.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Fluoxetine?
In FDA FAERS, the most frequently co-reported reaction terms for Fluoxetine are nausea, fatigue, headache, depression, anxiety, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Fluoxetine have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: SUICIDAL THOUGHTS AND BEHAVIORS • Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the r.
Do FAERS signals prove that Fluoxetine causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 05b0781b-50e2-4311-bde0-430b96e2ef8e, effective 20240712; matched on
openfda.generic_name.exact:"FLUOXETINE" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 3386 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,184 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
FLUOXETINE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.